ArticleThe Journal of clinical investigation1998
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.
- Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2023Pooled it
- Tumor NLRP3 amplification promotes immunotherapy resistance by inhibiting STAT1 signaling and MHC class I expression.The Journal of clinical investigation · 2026Article
- CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer.NPJ breast cancer · 2026Article
- Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors.bioRxiv : the preprint server for biology · 2026Article
- Article
- Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth.Cell reports · 2025Article
- Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Cell-intrinsic and microenvironmental determinants of metastatic colonization.Nature cell biology · 2024Review
- Universal cell donor lines: A review of the current research.Stem cell reports · 2023Review
- Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.International journal of molecular sciences · 2023Review
- Immunosuppressive Signaling Pathways as Targeted Cancer Therapies.Biomedicines · 2022Review
- The immune-related role of beta-2-microglobulin in melanoma.Frontiers in oncology · 2022Review
- Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker.Journal of the National Cancer Institute · 2021Review
- The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.BMC cancer · 2021Article
- Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.CNS neuroscience & therapeutics · 2021Article
- Tumor microenvironment of adult T-cell leukemia/lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2021Review
- Overcoming Immune Evasion in Melanoma.International journal of molecular sciences · 2020Review
- Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.International journal of molecular sciences · 2020Review
- How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.Cancer research · 2020Review
- Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The potential negative impact of HLA class I antigen abnormalities on the outcome of T cell-based immunotherapy of melanoma has prompted us to investigate the mechanisms underlying lack of HLA class I antigen expression by melanoma cell lines Me18105, Me9923, and Me1386. Distinct mutations in the beta2-microglobulin (beta2m) gene were identified in each cell line which result in loss of functional beta2m. In Me18105 cells, an aberrant splicing mechanism caused by an A--> G point mutation in the splice acceptor site of intron 1 of the beta2m gene, deletes 11 bp from the beta2m mRNA creating a shift in the reading frame. In Me9923 cells a 14-bp deletion in exon 2 and in Me1386 cells a CT deletion in exon 1 of the beta2m gene produce a frameshift mutation. The beta2m gene mutations identified in Me18105, Me9923, and Me1386 cells were also detected in the surgically removed melanoma lesions from which the cell lines originated. Transfection of each melanoma cell line with a wild-type beta2m gene restored HLA class I antigen expression and, in Me18105 cells, recognition by Melan-A/MART-1-specific, HLA-A2-restricted cytotoxic T lymphocytes. Interestingly, the beta2m mutation present in Me9923 cells that were derived from a metastatic lesion was also found in the Me9923P cell line that originated from the autologous primary lesion. These data suggest that beta2m mutations in melanoma cells may be an early event in progression to the malignant phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.